Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review)

International Journal of Oncology

Volumn 45, Issue 3, 2014, Pages 909-918

  Evangelisti, Camilla ^a   Evangelisti, Cecilia ^b   Chiarini, Francesca ^a   Lonetti, Annalisa ^b   Buontempo, Francesca ^b   Bressanin, Daniela ^b   Cappellini, Alessandra ^c   Orsini, Ester ^b   McCubrey, James A ^d   Martelli, Alberto M ^b  

^a CNR   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

^d EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Leukemia initiating cells; Mammalian target of rapamycin; T acute lymphoblastic leukemia; Targeted therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; ANTINEOPLASTIC AGENT; TARGET OF RAPAMYCIN KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; AEROBIC METABOLISM; AUTOPHAGY; BINDING SITE; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMOGENESIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; T CELL ACUTE LYMPHOBLASTIC LEUKEMIA; T LYMPHOCYTE; T-CELL LEUKEMIA CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MOLECULAR TARGETED THERAPY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84904383690     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2525     Document Type: Review

References (149)

1. Farhi DC and Rosenthal NS: Acute lymphoblastic leukemia. Clin Lab Med 20: 17-28, 2000. (Pubitemid 30111888)
2. Mullighan CG: Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest 122: 3407-3415, 2012.
3. Brown C: The genomics revolution: relevance in healthcare today and tomorrow. J R Coll Physicians Edinb 42: 248-250, 2012.
4. Zhao WL: Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways. Leukemia 24: 13-21, 2010.
5. Kox C, Zimmermann M, Stanulla M, et al: The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 24: 2005-2013, 2010.
6. Pui CH, Robison LL and Look AT: Acute lymphoblastic leukaemia. Lancet 371: 1030-1043, 2008. (Pubitemid 351389536)
7. Koch U and Radtke F: Notch in T-ALL: new players in a complex disease. Trends Immunol 32: 434-442, 2011.
8. Hoelzer D and Gokbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma 9: S214-S221, 2009.
9. Alharbi RA, Pettengell R, Pandha HS and Morgan R: The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 27: 1000-1008, 2013.
10. Iacobucci I, Papayannidis C, Lonetti A, Ferrari A, Baccarani M and Martinelli G: Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments. Curr Hematol Malig Rep 7: 133-143, 2012.
11. Bains T, Heinrich MC, Loriaux MM, et al: Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia. Leukemia 26: 2144-2146, 2012.
12. Jenkinson S, Koo K, Mansour MR, et al: Impact of NOTCH1/ FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial. Leukemia 27: 41-47, 2013.
13. Blackburn JS, Liu S, Raiser DM, et al: Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia 26: 2069-2078, 2012.
14. Lhermitte L, Ben Abdelali R, Villarese P, et al: Receptor kinase profiles identify a rationale for multitarget kinase inhibition in immature T-ALL. Leukemia 27: 305-314, 2013.
15. Cialfi S, Palermo R, Manca S, et al: Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression. Leukemia 27: 485-488, 2013.
16. Malyukova A, Brown S, Papa R, et al: FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. Leukemia 27: 1053-1062, 2013.
17. Correia NC, Durinck K, Leite AP, et al: Novel TAL1 targets beyond protein-coding genes: identification of TAL1-regulated microRNAs in T-cell acute lymphoblastic leukemia. Leukemia 27: 1603-1606, 2013.
18. Lv M, Zhang X, Jia H, et al: An oncogenic role of miR-142-3p in human T-cell acute lymphoblastic leukemia (T-ALL) by targeting glucocorticoid receptor-a and cAMP/PKA pathways. Leukemia 26: 769-777, 2012.
19. Schotte D, Pieters R and Den Boer ML: MicroRNAs in acute leukemia: from biological players to clinical contributors. Leukemia 26: 1-12, 2012.
20. Tosello V and Ferrando AA: The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol 4: 199-210, 2013.
21. Van Vlierberghe P and Ferrando A: The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest 122: 3398-3406, 2012.
22. Buss EC and Ho AD: Leukemia stem cells. Int J Cancer 129: 2328-2336, 2011.
23. Clevers H: The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319, 2011.
24. Kreso A and Dick JE: Evolution of the cancer stem cell model. Cell Stem Cell 14: 275-291, 2014.
25. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS and Blair A: Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood 109: 674-682, 2007. (Pubitemid 46105969)
26. Chiu PP, Jiang H and Dick JE: Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance. Blood 116: 5268-5279, 2010.
27. Ma W, Gutierrez A, Goff DJ, et al: NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches. PloS One 7: e39725, 2012.
28. Gerby B, Clappier E, Armstrong F, et al: Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations. Leukemia 25: 1249-1258, 2011.
29. Silva A, Girio A, Cebola I, Santos CI, Antunes F and Barata JT: Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells. Leukemia 25: 960-967, 2011.
30. Benjamin D, Colombi M, Moroni C and Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 10: 868-880, 2011.
31. Lv X, Ma X and Hu Y: Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment. Expert Opin Drug Discov 8: 991-1012, 2013.
32. Dienstmann R, Rodon J, Serra V and Tabernero J: Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors. Mol Cancer Ther 13: 1021-1031, 2014.
33. Steelman LS, Franklin RA, Abrams SL, et al: Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 25: 1080-1094, 2011.
34. Memmott RM and Dennis PA: Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 21: 656-664, 2009.
35. Finlay MR and Griffin RJ: Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett 22: 5352-5359, 2012.
36. Laplante M and Sabatini DM: mTOR signaling in growth control and disease. Cell 149: 274-293, 2012.
37. Zoncu R, Efeyan A and Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35, 2011.
38. Fingar DC and Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004. (Pubitemid 38638827)
39. Inoki K, Li Y, Zhu T, Wu J and Guan KL: TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657, 2002. (Pubitemid 34993700)
40. Volkers M and Sussman M: mTOR/PRAS40 interaction: hypertrophy or proliferation. Cell Cycle 12: 3579-3580, 2013.
41. Laplante M and Sabatini DM: mTOR signaling at a glance. J Cell Sci 122: 3589-3594, 2009.
42. Browne GJ and Proud CG: A novel mTOR-regulated phosphorylation site in elongation f actor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol Cell Biol 24: 2986-2997, 2004. (Pubitemid 38381287)
43. Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318, 2009.
44. McCubrey JA, Steelman LS, Chappell WH, et al: Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 3: 954-987, 2012.
45. Martelli AM, Evangelisti C, Chappell W, et al: Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 25: 1064-1079, 2011.
46. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK and Puigserver P: mTOR controls mitochondrial oxidative function through a YY1-PGC-1a transcriptional complex. Nature 450: 736-740, 2007. (Pubitemid 350207689)
47. Majumder PK, Febbo PG, Bikoff R, et al: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601, 2004.
48. Yecies JL and Manning BD: Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 71: 2815-2820, 2011.
49. Levine B and Kroemer G: Autophagy in the pathogenesis of disease. Cell 132: 27-42, 2008.
50. Hosokawa N, Hara T, Kaizuka T, et al: Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 20: 1981-1991, 2009.
51. Mizushima N: The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 22: 132-139, 2010.
52. Zeng Z, Sarbassov dos D, Samudio IJ, et al: Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109: 3509-3512, 2007.
53. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
54. Garcia-Martinez JM and Alessi DR: mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416: 375-385, 2008.
55. Ikenoue T, Inoki K, Yang Q, Zhou X and Guan KL: Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J 27: 1919-1931, 2008.
56. Oh WJ and Jacinto E: mTOR complex 2 signaling and functions. Cell Cycle 10: 2305-2316, 2011.
57. Tamburini J, Green AS, Chapuis N, et al: Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Cell Cycle 8: 3893-3899, 2009.
58. Shah OJ, Wang Z and Hunter T: Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650-1656, 2004. (Pubitemid 39239362)
59. Bhaskar PT and Hay N: The two TORCs and Akt. Dev Cell 12: 487-502, 2007. (Pubitemid 46523652)
60. Lang SA, Hackl C, Moser C, et al: Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells. Biochim Biophys Acta 1803: 435-442, 2010.
61. Xu X, Sarikas A, Dias-Santagata DC, et al: The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol Cell 30: 403-414, 2008. (Pubitemid 351672370)
62. Sriburi R, Jackowski S, Mori K and Brewer JW: XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J Cell Biol 167: 35-41, 2004. (Pubitemid 39363412)
63. Boulbes D, Chen CH, Shaikenov T, et al: Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res 8: 896-906, 2010.
64. Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378, 1998. (Pubitemid 28268370)
65. Sansal I and Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963, 2004. (Pubitemid 41079915)
66. Kalesnikoff J, Sly LM, Hughes MR, et al: The role of SHIP in cytokine-induced signaling. Rev Physiol Biochem Pharmacol 149: 87-103, 2003.
67. Liu Q, Sasaki T, Kozieradzki I, et al: SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev 13: 786-791, 1999. (Pubitemid 29169837)
68. Bunney TD and Katan M: Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 10: 342-352, 2010.
69. Seshacharyulu P, Pandey P, Datta K and Batra SK: Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 335: 9-18, 2013.
70. Guo W, Lasky JL, Chang CJ, et al: Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 453: 529-533, 2008. (Pubitemid 351733319)
71. Guo W, Schubbert S, Chen JY, et al: Suppression of leukemia development caused by PTEN loss. Proc Natl Acad Sci USA 108: 1409-1414, 2011.
72. Hoshii T, Kasada A, Hatakeyama T, et al: Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc Natl Acad Sci USA 111: 3805-3810, 2014.
73. Kang SA, Pacold ME, Cervantes CL, et al: mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341: 1236566, 2013.
74. Chiarini F, Fala F, Tazzari PL, et al: Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 69: 3520-3528, 2009.
75. Evangelisti C, Ricci F, Tazzari P, et al: Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia 25: 781-791, 2011.
76. Bressanin D, Evangelisti C, Ricci F, et al: Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget 3: 811-823, 2012.
77. Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL and Morrison SJ: Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11: 415-428, 2012.
78. Mullighan CG: Genomic profiling of B-progenitor acute lymphoblastic leukemia. Best Pract Res Clin Haematol 24: 489-503, 2011.
79. Inaba H, Greaves M and Mullighan CG: Acute lymphoblastic leukaemia. Lancet 381: 1943-1955, 2013.
80. Jotta PY, Ganazza MA, Silva A, et al: Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 24: 239-242, 2010.
81. Karrman K, Forestier E, Heyman M, et al: Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome. Genes Chromosomes Cancer 48: 795-805, 2009.
82. Martelli AM, Chiarini F, Evangelisti C, et al: Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 3: 371-394, 2012.
83. Nemes K, Sebestyen A, Mark A, et al: Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL). PLoS One 8: e59335, 2013.
84. Gutierrez A, Sanda T, Grebliunaite R, et al: High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114: 647-650, 2009.
85. Bandapalli OR, Zimmermann M, Kox C, et al: NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica 98: 928-936, 2013.
86. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al: Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 31: 4333-4342, 2013.
87. Grossmann V, Haferlach C, Weissmann S, et al: The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL. Genes Chromosomes Cancer 52: 410-422, 2013.
88. Palomero T, Sulis ML, Cortina M, et al: Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med 13: 1203-1210, 2007. (Pubitemid 47530629)
89. Palomero T, Lim WK, Odom DT, et al: NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA 103: 18261-18266, 2006. (Pubitemid 44871646)
90. Gutierrez A, Grebliunaite R, Feng H, et al: Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med 208: 1595-1603, 2011.
91. Mavrakis KJ, Wolfe AL, Oricchio E, et al: Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nat Cell Biol 12: 372-379, 2010.
92. Silva A, Yunes JA, Cardoso BA, et al: PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest 118: 3762-3774, 2008.
93. Hales EC, Orr SM, Larson Gedman A, Taub JW and Matherly LH: Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells. J Biol Chem 288: 22836-22848, 2013.
94. Medyouf H, Gusscott S, Wang H, et al: High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med 208: 1809-1822, 2011.
95. Cardoso BA, Martins LR, Santos CI, et al: Interleukin-4 stimulates proliferation and growth of T-cell acute lymphoblastic leukemia cells by activating mTOR signaling. Leukemia 23: 206-208, 2009.
96. Barata JT, Silva A, Brandao JG, Nadler LM, Cardoso AA and Boussiotis VA: Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. J Exp Med 200: 659-669, 2004. (Pubitemid 39258314)
97. Scupoli MT, Vinante F, Krampera M, et al: Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. Haematologica 88: 1229-1237, 2003. (Pubitemid 37456377)
98. Zenatti PP, Ribeiro D, Li W, et al: Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 43: 932-939, 2011.
99. Wong D and Korz W: Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 14: 7975-7980, 2008.
100. Scupoli MT, Donadelli M, Cioffi F, et al: Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-κB and JNK/AP-1 pathways. Haematologica 93: 524-532, 2008. (Pubitemid 351536380)
101. Pillozzi S, Masselli M, De Lorenzo E, et al: Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117: 902-914, 2011.
102. Heitman J, Movva NR and Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909, 1991. (Pubitemid 21917235)
103. Zhou H, Luo Y and Huang S: Updates of mTOR inhibitors. Anticancer Agents Med Chem 10: 571-581, 2010.
104. Schuler W, Sedrani R, Cottens S, et al: SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64: 36-42, 1997. (Pubitemid 27327197)
105. Avellino R, Romano S, Parasole R, et al: Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106: 1400-1406, 2005. (Pubitemid 41129607)
106. Chan SM, Weng AP, Tibshirani R, Aster JC and Utz PJ: Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood 110: 278-286, 2007. (Pubitemid 47026845)
107. Wu KN, Zhao YM, He Y, et al: Rapamycin interacts synergistically with idarubicin to induce T-leukemia cell apoptosis in vitro and in a mesenchymal stem cell simulated drug-resistant microenvironment via Akt/mammalian target of rapamycin and extracellular signal-related kinase signaling pathways. Leuk Lymphoma 55: 668-676, 2014.
108. Akers LJ, Fang W, Levy AG, Franklin AR, Huang P and Zweidler-McKay PA: Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin. Leukemia Res 35: 814-820, 2011.
109. Batista A, Barata JT, Raderschall E, et al: Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 39: 457-472 e453, 2011.
110. Houghton PJ, Morton CL, Kolb EA, et al: Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 799-805, 2008. (Pubitemid 351354788)
111. Yee KW, Zeng Z, Konopleva M, et al: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12: 5165-5173, 2006. (Pubitemid 44453345)
112. Rizzieri DA, Feldman E, Dipersio JF, et al: A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14: 2756-2762, 2008.
113. Tamburini J, Green AS, Bardet V, et al: Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 114: 1618-1627, 2009.
114. Chiarini F, Grimaldi C, Ricci F, et al: Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 70: 8097-8107, 2010.
115. Fox CJ, Hammerman PS and Thompson CB: The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med 201: 259-266, 2005. (Pubitemid 40189435)
116. Zhang F, Beharry ZM, Harris TE, et al: PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 8: 846-853, 2009.
117. Lin YW, Beharry ZM, Hill EG, et al: A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 115: 824-833, 2010.
118. Tamburini J, Chapuis N, Bardet V, et al: Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 111: 379-382, 2008.
119. Carracedo A, Ma L, Teruya-Feldstein J, et al: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074, 2008.
120. Efeyan A and Sabatini DM: mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22: 169-176, 2010.
121. Bertacchini J, Guida M, Accordi B, et al: Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia: Apr 4, 2014 (E-pub ahead of print).
122. Park S, Chapuis N, Saint Marcoux F, et al: A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia 27: 1479-1486, 2013.
123. Daver N, Kantarjian H, Thomas D, et al: A phase I/II study of hyper-CVAD plus everolimus in patients with relapsed/refractory acute lymphoblastic leukemia. 55th ASH Annual Meeting. Blood 122: abs. 3916, 2013.
124. Fan QW, Knight ZA, Goldenberg DD, et al: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349, 2006. (Pubitemid 43668732)
125. Cho DC, Cohen MB, Panka DJ, et al: The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 16: 3628-3638, 2010.
126. Karar J, Cerniglia GJ, Lindsten T, Koumenis C and Maity A: Dual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia. Cancer Biol Ther 13: 1102-1111, 2012.
127. Schenone S, Brullo C, Musumeci F, Radi M and Botta M: ATP-competitive inhibitors of mTOR: an update. Curr Med Chem 18: 2995-3014, 2011.
128. Shepherd C, Banerjee L, Cheung CW, et al: PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Leukemia 27: 650-660, 2013.
129. Raynaud FI, Eccles S, Clarke PA, et al: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67: 5840-5850, 2007. (Pubitemid 46985018)
130. Maira SM, Stauffer F, Brueggen J, et al: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
131. Schult C, Dahlhaus M, Glass A, et al: The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Anticancer Res 32: 463-474, 2012.
132. Shortt J, Martin BP, Newbold A, et al: Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 121: 2964-2974, 2013.
133. Woods D and Turchi JJ: Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther 14: 379-389, 2013.
134. Kampa-Schittenhelm KM, Heinrich MC, Akmut F, et al: Cell cycle-dependent activity of the novel dual PI3K-mTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer 12: 46, 2013.
135. Soria JC, Cortes J, Massard C, et al: Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Ann Oncol 23: 463-471, 2012.
136. Janes MR, Limon JJ, So L, et al: Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213, 2010.
137. Garcia-Echeverria C and Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-5526, 2008.
138. Garcia-Echeverria C: Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment. Bioorg Med Chem Lett 20: 4308-4312, 2010.
139. Gentzler RD, Altman JK and Platanias LC: An overview of the mTOR pathway as a target in cancer therapy. Expert Opin Ther Targets 16: 481-489, 2012.
140. Altman JK, Sassano A, Kaur S, et al: Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 17: 4378-4388, 2011.
141. Willems L, Chapuis N, Puissant A, et al: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 26: 1195-1202, 2012.
142. Gupta M, Hendrickson AE, Yun SS, et al: Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119: 476-487, 2012.
143. Feldman ME, Apsel B, Uotila A, et al: Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38, 2009.
144. Janes MR, Vu C, Mallya S, et al: Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 27: 586-594, 2013.
145. Peng C, Chen Y, Li D and Li S: Role of Pten in leukemia stem cells. Oncotarget 1: 156-160, 2010.
146. Yilmaz OH, Valdez R, Theisen BK, et al: Pten dependence distinguishes haematopoietic stem cells from leukaemiainitiating cells. Nature 441: 475-482, 2006. (Pubitemid 44050144)
147. Kaplan B, Qazi Y and Wellen JR: Strategies for the management of adverse events associated with mTOR inhibitors. Transplant Rev: Mar 12, 2014 (Epub ahead of print).
148. Markman B, Tabernero J, Krop I, et al: Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann Oncol 23: 2399-2408, 2012.
149. Mallya S, Fitch BA, Lee JS, So L, Janes MR and Fruman DA: Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. PloS One 9: e88865, 2014.